

# GRAPHICAL ABSTRACT SAMPLE WORK

**GSTO1 as a Potential Risk Factor for Diabetic Nephropathy: Evidence  
from Mendelian Randomisation and Multi-Omics Analyses**


GSTO1 as a Potential Risk Factor for Diabetic Nephropathy: Evidence from Mendelian Randomization and Multi-Omics Analyses

Aim:

This study aimed to investigate the potential causal relationship between GSTO1 and DN risk.

Methods:

Two-sample MR analysis




Results:

GSTO1 may be associated with DKD risk and is upregulated in DKD.

| exposure | outcome              | nsnp | method                    | pval  | OR(95% CI)             |
|----------|----------------------|------|---------------------------|-------|------------------------|
| GSTO1    | Diabetic nephropathy | 70   | MR Egger                  | 0.342 | 1.045 (0.954 to 1.145) |
| GSTO1    | Diabetic nephropathy | 70   | Weighted median           | 0.391 | 1.035 (0.956 to 1.121) |
| GSTO1    | Diabetic nephropathy | 70   | Inverse variance weighted | 0.008 | 1.071 (1.017 to 1.128) |
| GSTO1    | Diabetic nephropathy | 70   | Simple mode               | 0.325 | 0.983 (0.842 to 1.147) |
| GSTO1    | Diabetic nephropathy | 70   | Weighted mode             | 0.411 | 1.042 (0.945 to 1.150) |

| exposure             | outcome | nsnp | method                    | pval  | OR(95% CI)             |
|----------------------|---------|------|---------------------------|-------|------------------------|
| Diabetic nephropathy | GSTO1   | 33   | MR Egger                  | 0.191 | 0.971 (0.931 to 1.014) |
| Diabetic nephropathy | GSTO1   | 33   | Weighted median           | 0.060 | 0.973 (0.944 to 1.002) |
| Diabetic nephropathy | GSTO1   | 33   | Inverse variance weighted | 0.072 | 0.982 (0.962 to 1.002) |
| Diabetic nephropathy | GSTO1   | 33   | Simple mode               | 0.609 | 0.987 (0.938 to 1.038) |
| Diabetic nephropathy | GSTO1   | 33   | Weighted mode             | 0.144 | 0.970 (0.945 to 1.006) |



**CONCLUSION:** GSTO1 may be a candidate molecular marker and potential therapeutic target for diabetic nephropathy.